Company
Agilent Technologies
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
18
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
8
Received Nov 1, 2025 to Nov 20, 2026
Recall records
9
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
A
NYSE · AGILENT TECHNOLOGIES, INC.
Public float
Unknown
Not reported in US filings
Revenue
$6.95B
Fiscal year ending Oct 31, 2025
Net income
$1.30B
Fiscal year ending Oct 31, 2025
R&D spending
$455M
Fiscal year ending Oct 31, 2025
Cash
$1.76B
As of Jul 31, 2026
Long-term debt
$3.65B
As of Jul 31, 2026
Shares outstanding
281.9M
As of Aug 26, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $4.0M | – |
| 2024 | – | – | $1.20B | – |
| 2022 | – | – | $600M | – |
| 2021 | – | – | $848M | – |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 18 since 2015.
- PD-L1 IHC 28-8 pharmDxPMA supplement
P150025-S018 · Decided Jul 1, 2026 · 180 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S032 · Decided Feb 11, 2026 · 187 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
- PD-L1 IHC 22C3 pharmDxPMA supplement
P150013-S033 · Decided Feb 10, 2026 · 134 days after receipt · Panel Track
Device type: Immunohistochemistry assay, antibody, programmed death-ligand 1 (PLS) · Laboratory Medicine & Pathology
15 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
8
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
7
88% of reports
Injury reports
1
13% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 11 | 0 | 0 | 0 |
| Jan 24 | 9 | 0 | 0 | 0 |
| Feb 24 | 5 | 0 | 0 | 0 |
| Mar 24 | 6 | 0 | 0 | 0 |
| Apr 24 | 11 | 0 | 0 | 0 |
| May 24 | 7 | 0 | 0 | 0 |
| Jun 24 | 7 | 0 | 0 | 0 |
| Jul 24 | 5 | 0 | 0 | 0 |
| Aug 24 | 5 | 0 | 0 | 0 |
| Sep 24 | 9 | 1 | 0 | 0 |
| Oct 24 | 4 | 0 | 0 | 0 |
| Nov 24 | 9 | 0 | 0 | 0 |
| Dec 24 | 12 | 0 | 0 | 0 |
| Jan 25 | 5 | 0 | 0 | 0 |
| Feb 25 | 11 | 0 | 0 | 0 |
| Mar 25 | 5 | 0 | 0 | 0 |
| Apr 25 | 11 | 0 | 0 | 0 |
| May 25 | 8 | 0 | 0 | 0 |
| Jun 25 | 1 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 2 | 0 | 0 | 0 |
| Sep 25 | 1 | 0 | 0 | 0 |
| Oct 25 | 3 | 0 | 0 | 0 |
| Nov 25 | 2 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 0 | 1 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 1 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
3 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2563-2025 · Started Aug 11, 2025 · Posted by FDA Sep 15, 2025
Reason given: Their is the potential for weak staining which may result in false negative CD20 identification.
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunohistochemistry Reagents And Kits (NJT)
Z-2564-2025 · Started Aug 11, 2025 · Posted by FDA Sep 15, 2025
Reason given: Their is the potential for weak staining which may result in false negative CD20 identification.
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunohistochemistry Reagents And Kits (NJT)
Z-2565-2025 · Started Aug 11, 2025 · Posted by FDA Sep 15, 2025
Reason given: Their is the potential for weak staining which may result in false negative CD20 identification.
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunohistochemistry Reagents And Kits (NJT)
6 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.